Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy

Table 3 The effect of risk factors on all-cause mortality – Univariate and multiple logistic regression analysis

Risk Factors^{a, b}	Unadjusted OR	95 % CI	p-value	Adjusted OR	95 % CI	p-value
Years post-chemo	0.62	0.54, 0.70	<0.001	0.62	0.54, 0.71	<0.001
Age at Diagnosis (yrs)	1.05	1.01, 1.10	0.02	0.94	0.87, 1.02	0.12
Gender	0.69	0.42, 1.16	0.16	---	---	---
Cumulative dose	3.77	2.12, 6.71	<0.001	3.17	1.14, 8.85	0.03
Radiation to chest	1.32	0.66, 2.67	0.43	---	---	---
Vinca Alkaloids	0.32	0.19, 0.54	<0.001	0.37	0.13, 1.08	0.07
Previous SF < 29 %	4.52	2.62, 7.79	<0.001	6.54	2.40, 17.81	<0.001
BMT	4.21	2.19, 8.09	<0.001	5.22	1.57, 17.37	0.007
Previous heart disease	1.66	0.76, 3.61	0.20	---	---	---
Cardio-protective drugs	0.71	0.21, 2.39	0.58	---	---	---
Solid Tumor Diagnosis	3.2	1.94, 5.42	<0.001	4.13	1.72, 9.87	0.001

^aRisk factors for cardiotoxicity include increased length of post-chemotherapy interval (years), younger age at diagnosis, female gender, total cumulative dose ≥240 mg/m², radiation therapy to the chest, treatment with vinca alkaloids, previous shortening fraction < 29 %, bone marrow transplant, previous heart disease, non-use of cardio-protective drugs, solid tumor diagnosis
^bThe 7 significant risk factors upon univariate analysis were selected as covariates for the multiple logistic regression model (increased length post-chemotherapy interval, younger age at diagnosis, total cumulative dose anthracyclines > 240 mg/m², use of vinca alkaloids, previous SF < 29 %, BMT, and solid tumor diagnosis)

ISSN: 2057-3804